Vaxcyte, Inc.

XNASHealth care

Last traded price · USD

$63.42

−3.44%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: $65.88
Previous close: $65.68
Volume: 289,380
Day's high: $65.88
Day's low: $63.16

In brief

Vaxcyte, Inc. is a health care company listed on Nasdaq, valued at about $9.98B.
Its shares closed at $65.68 on 4 Nov 2026, up 58.8% over the past year.
From India you can buy PCVX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vaxcyte, Inc. (PCVX) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole PCVX share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade PCVX options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.5% (SPY −1.6%, XLV +13.5%). 3 months: +17.5% (SPY −0.4%, XLV +15.5%). 1 year: +58.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PCVX, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $65.68 was 6.6% above its 50-day average ($61.64) and 14.7% above its 200-day average ($57.26). It has closed above the 200-day for 100 sessions, since 15 Jun 2026. The 50-day average crossed above the 200-day on 26 Nov 2025, 235 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
50% of the way up its 52-week range
Closed at $65.68 on 4 Nov 2026: 27.6% below the 52-week high of $90.75 (5 Oct 2026) and 63.6% above the low of $40.14 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 9.8% of shares outstanding
14.6M shares were sold short at the 15 Oct 2026 settlement, 9.8% of the 148.8M shares outstanding; covering them would take 2.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.5%

6 months+15.0%

1 year+58.8%

5 years+163.2%

Newswire

About

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.

Website

Notable moves

March 31, 2025
−45.64%
September 3, 2024
+36.39%
October 24, 2022
+60.35%

Vaxcyte, Inc.

XNASHealth care

Last traded price · USD

$63.42

−3.44%Delayed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 21:14 IST · A quote does not mean the product is available to trade on your account.

Day's open: $65.88
Previous close: $65.68
Volume: 289,380
Day's high: $65.88
Day's low: $63.16

In brief

Vaxcyte, Inc. is a health care company listed on Nasdaq, valued at about $9.98B.
Its shares closed at $65.68 on 4 Nov 2026, up 58.8% over the past year.
From India you can buy PCVX in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy Vaxcyte, Inc. (PCVX) shares from India?

Do I need the price of a whole PCVX share to invest?

How much can I invest in US stocks in a year?

Can I trade PCVX options or futures?

Insights

Quotes run fifteen minutes behind.

Ahead of SPY and its sector fund XLV over 1 year
1 month: −1.5% (SPY −1.6%, XLV +13.5%). 3 months: +17.5% (SPY −0.4%, XLV +15.5%). 1 year: +58.8% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: PCVX, SPY and XLV · as of 4 Nov 2026
Above its 50- and 200-day averages
The 4 Nov 2026 close of $65.68 was 6.6% above its 50-day average ($61.64) and 14.7% above its 200-day average ($57.26). It has closed above the 200-day for 100 sessions, since 15 Jun 2026. The 50-day average crossed above the 200-day on 26 Nov 2025, 235 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
50% of the way up its 52-week range
Closed at $65.68 on 4 Nov 2026: 27.6% below the 52-week high of $90.75 (5 Oct 2026) and 63.6% above the low of $40.14 (7 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
Short interest at 9.8% of shares outstanding
14.6M shares were sold short at the 15 Oct 2026 settlement, 9.8% of the 148.8M shares outstanding; covering them would take 2.9 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−1.5%

6 months+15.0%

1 year+58.8%

5 years+163.2%

Newswire

About

Website

Notable moves

March 31, 2025
−45.64%
September 3, 2024
+36.39%
October 24, 2022
+60.35%

Vaxcyte, Inc.

Vaxcyte, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

50% of the way up its 52-week range

Short interest at 9.8% of shares outstanding

Vaxcyte, Inc.

Vaxcyte, Inc. in brief

Ahead of SPY and its sector fund XLV over 1 year

Above its 50- and 200-day averages

50% of the way up its 52-week range

Short interest at 9.8% of shares outstanding